PRECeDI - Personalized pREvention of Chronic DIseases
PRECeDI promotes international and inter-sector collaboration through research and innovation staff exchanges, and sharing of knowledge and ideas from research to market (and vice-versa) for the advancement of science and the development of innovation. EUPHA is one of the partners hosting researchers from other organisations. In hosting the researchers, EUPHA closely works together with the Department of Clinical Genetics, VU University Medical Centre, Amsterdam.
The aim of the PRECeDI consortium is to promote knowledge transfer between academic and non-academic entities that can lead to a proper integration of –omics information into public health interventions. The main goal of this platform is to cover an existing gap in the evidence-base use of the –omics approach in the prevention of chronic diseases, by sharing knowledge, building synergies and expertise and encouraging an exchange of best practice among top-level institutions. In the long run, the results of the consortium activities will enhance the scientific basis for an appropriate implementation of the –omics applications into true benefits for population health.
PRECeDI facilitates collaboration in the form of joint research and innovation activities across five domains of personalized prevention of chronic diseases:
- Identification of biomarkers for the prevention of chronic diseases
- Economic evaluation of predictive genomic applications
- Ethico-legal and policy issues surrounding personalized medicine
- Sociotechnical analysis of the pros-and cons of informing healthy individuals on their genome
- Identification of organizational models for the provision of predictive genetic testing
The PRECeDI project has received funding from the European Union’s Horizon 2020 research and innovation programme Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) under the grant agreement No. 645740.
PRECeDI is coordinated by the Catholic University of the Sacred Heart of Rome (Italy). The consortium consists of 11 partners from different European Countries, USA, Canada, of which 7 are academic institutions and 4 non academic organisations, including EUPHA.
EUPHA hosted Peter Piko from the University of Debrecen who worked on the pros and cons of informing healthy individuals on their genome (primary prevention healthy family members). The analysis focused on how actively healthy family members of index patients can or should be traced and informed on genetic testing.
Researchers from the Sapienza University of Rome, Annalisa Rosso and Valentina Baccolini, are working on a survey aimed at assessing European public health professionals’ knowledge and attitudes regarding the practical application of Public Health Genomics (PHG).
Alessia Tognetto, Catholic University of the Sacred Heart of Rome, is seconded to EUPHA and working on an economic evaluation of predictive genetic test: cost-effectiveness analysis on screening genetic testing for Lynch Syndrome.
More information on the project website.